Clinical research of treatment to carotid atherosclerosis with rosuvastatin in stage 4～5 chronic kidney disease

Objective To investigate the effects of rosuvastatin on carotid atherosclerosis plaques in patients with stage 4/5 chronic kidney disease.Methods A total of 90 stage 4~5 chronic kidney disease patients with carotid atherosclerosis plaques were randomized to rosuvastatin 5 mg·d-1(group A,n=30),rosuvastatin 10 mg·d-1(group B,n=30) and atorvastatin 10 mg·d-1(group C,n=30) for twelve months.The three groups matched for age and gender.The blood lipids including total cholesterol,triglyceride,low density lipoprotein cholesterol and high density lipoprotein cholesterol,highly sensitive C-reactive protein,hepatic function(ALT),creatine kinase(CK),the intima-media thickness(IMT) of carotid arteries,plaque morphology were evaluated before and after treatment.Results The blood lipids levels,the hs-CRP,and the carotid atherosclerosis plaques of three groups before treatment had no significant differences(P0.05).The TC,TG,LDL-C,hs-CRP levels of three groups after treatment for 12 months were significantly decreased compared with before treatment(P0.01),while the HDL-C was increased(P0.01).The change of B group was more apparent than A and C group(P0.01).The IMT after treatment was thinner than before treatment,and there was no significant difference except that in B group(P0.05).After treatment,the count of plaques was not statistically significant among three groups,while the size was significantly decreased in B group.Conclusion Rosuvastatin(10 mg·d-1) can reverse the carotid atherosclerosis plaques in patients with stage 4~5 chronic kidney disease safely.